Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology

Why is Lp(a) so dangerous when it circulates at a fraction of LDL’s concentration? This focused review from the field’s leading lab points to the answer carried on the particle itself: oxidized phospholipids.

Lp(a) is the bloodstream’s preferred carrier of these inflammatory molecules, and a portion are chemically bolted onto a specific site (the KIV10 domain) of its signature protein. The authors marshal elegant proof: mutate that binding site so oxidized phospholipids can’t attach, and much of Lp(a)‘s harm disappears. Those molecules, not the cholesterol, prime monocytes, activate the endothelium, and drive the valve-cell calcification behind aortic stenosis — which explains why Lp(a) causes both atherosclerosis and valve disease.

The practical takeaway reframes Lp(a) as an inflammatory particle, not just “more cholesterol” — which is why lowering it, along with its oxidized-phospholipid cargo, is the therapeutic goal, and why antibody strategies against those molecules are of interest.

We rate the evidence strong for a mechanistic review: authoritative, with the binding-site experiments providing real causal weight. The authors candidly flag the gap — direct in vivo proof is still thin and the exact molecular species undefined. Its clinical significance is high: it underpins the rationale for the Lp(a)-lowering trials now underway and explains the linked risk of artery and valve disease in high-Lp(a) patients.